Market Overview

UPDATE: Goldman Sachs Raises PT to $170 on Regeneron Pharmaceuticals on Eylea EU Approval

Share:
Related REGN
Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in Asthma
Credit Suisse: Regeneron Now Worth $550/Share
Top Biotech Stock Illumina Hunts For Breakout Gene (Investor's Business Daily)

Goldman Sachs reiterated its Buy rating on Regeneron Pharmaceuticals (NASDAQ: REGN) and increased its price target from $168 to $170.

Goldman Sachs noted, "FDA approved REGN's Eylea for a new eye disease indication (central retinal vein occlusion, CRVO), in line with our expectation. Eylea was approved last year for the wet AMD indication. We model 2013 US Eylea sales of $1.2bn (62% yoy growth) of which CRVO contributes $104mn."

Regeneron Pharmaceuticals closed at $145.09 on Friday.

Latest Ratings for REGN

DateFirmActionFromTo
May 2015CitigroupMaintainsBuy
May 2015Credit SuisseAssumesOutperform
May 2015Leerink SwannMaintainsOutperform

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (REGN)

Around the Web, We're Loving...